V
Verona Buocikova
Researcher at Slovak Academy of Sciences
Publications - 12
Citations - 100
Verona Buocikova is an academic researcher from Slovak Academy of Sciences. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 5 publications receiving 36 citations.
Papers
More filters
Journal ArticleDOI
Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
Silvia Schmidtova,Katarina Kalavska,Katarina Kalavska,Katarina Gercakova,Zuzana Cierna,Svetlana Miklikova,Bozena Smolkova,Verona Buocikova,Viera Miskovska,Erika Durinikova,Monika Burikova,Michal Chovanec,Miroslava Matuskova,Michal Mego,Lucia Kucerova +14 more
TL;DR: A novel clinically relevant model of chemoresistant TGCTs is characterized, for the first time identified the ALDH1A3 as a therapeutic target inTGCTs and more importantly, showed that disulfiram represents a viable treatment option for refractory TG CTs.
Journal ArticleDOI
Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
Verona Buocikova,Ivan Rios-Mondragon,Eleftherios Pilalis,Aristotelis Chatziioannou,Svetlana Miklikova,Michal Mego,Karlis Pajuste,Martins Rucins,Naouale El Yamani,Eleonora Longhin,Arkadij Sobolev,Muriel Freixanet,Víctor F. Puntes,Aiva Plotniece,Maria Dusinska,Mihaela Roxana Cimpan,Alena Gábelová,Bozena Smolkova +17 more
TL;DR: An overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment is provided and the latest nano-based targeted delivery approaches forEpigenome modulation are summarized, highlighting the current limitations and obstacles associated with applying these experimental strategies in the clinics.
Journal ArticleDOI
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Verona Buocikova,Eleonora Longhin,Eleftherios Pilalis,Chara V. Mastrokalou,Svetlana Miklikova,Marina Cihova,Alexandra Poturnayova,Kateřina Macková,Andrea Babelova,Lenka Trnkova,Naouale El Yamani,Congying Zheng,Ivan Rios-Mondragon,Martina Labudova,Lucia Csaderova,Kristina Kuracinova,Peter J. Makovicky,Lucia Kucerova,Miroslava Matuskova,Mihaela Roxana Cimpan,Maria Dusinska,Pavel Babal,Aristotelis Chatziioannou,Alena Gábelová,Elise Rundén-Pran,Bozena Smolkova +25 more
TL;DR: In this paper , the authors investigated the ability of DNA methyltransferase (DNMT) inhibitor decitabine (DAC) to increase the sensitivity of breast cancer cells to anthracycline antibiotic doxorubicin (DOX).
Journal ArticleDOI
A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients.
Iveta Zmetakova,Lenka Kalinkova,Bozena Smolkova,Viera Horvathova Kajabova,Zuzana Cierna,Ludovit Danihel,Martin Bohac,Tatiana Sedlackova,Gabriel Minarik,Marian Karaba,Juraj Benca,Marina Cihova,Verona Buocikova,Svetlana Miklikova,Michal Mego,Ivana Fridrichova +15 more
TL;DR: The results indicate that ADAM23 is likely involved in BC progression and dissemination of mesenchymal CTC and has the potential to function as a novel prognostic marker and therapeutic target.
Journal ArticleDOI
DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Mariana Urbanova,Verona Buocikova,Lenka Trnkova,Sabina Strapcova,Viera Horvathova Kajabova,Emma Barreto Melian,Maria Novisedlakova,Miroslav Tomas,Peter Dubovan,Julie Earl,Jozef Bizik,Eliska Svastova,Sona Ciernikova,Bozena Smolkova +13 more
TL;DR: The role of DNA methylation in EMT-related gene regulation is confirmed and possible new targets involved in PDAC progression are uncovered, including cancer inflammation and Immunity Crosstalk and Human Epithelial to Mesenchymal Transition.